Stock Track | Dianthus Therapeutics Soars 5.11% as Evercore ISI Maintains Buy Rating

Stock Track

Aug 12, 2025

Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught investors' attention as it demonstrates significant upward momentum.

The surge comes after Evercore ISI analyst Gavin Clark-Gartner reiterated a Buy rating on Dianthus Therapeutics stock. In a report released on Monday, Clark-Gartner maintained an optimistic outlook for the company, setting a price target of $50 for DNTH shares. This target suggests substantial upside potential from the stock's current trading levels.

Analyst ratings often play a crucial role in shaping investor sentiment, particularly for biotech companies like Dianthus Therapeutics. The maintained Buy rating and the ambitious price target indicate Evercore ISI's confidence in the company's pipeline and future prospects. As investors digest this positive assessment, it appears to be driving increased interest and buying activity in DNTH stock during the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197688629"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197688629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197688629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197688629","market":"nz","top_or_hot":-1,"title":"Stock Track | Dianthus Therapeutics Soars 5.11% as Evercore ISI Maintains Buy Rating","media":"Stock Track","content":"<p>Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught investors' attention as it demonstrates significant upward momentum.</p>\n\n<p>The surge comes after Evercore ISI analyst Gavin Clark-Gartner reiterated a Buy rating on Dianthus Therapeutics stock. In a report released on Monday, Clark-Gartner maintained an optimistic outlook for the company, setting a price target of $50 for DNTH shares. This target suggests substantial upside potential from the stock's current trading levels.</p>\n\n<p>Analyst ratings often play a crucial role in shaping investor sentiment, particularly for biotech companies like Dianthus Therapeutics. The maintained Buy rating and the ambitious price target indicate Evercore ISI's confidence in the company's pipeline and future prospects. As investors digest this positive assessment, it appears to be driving increased interest and buying activity in DNTH stock during the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dianthus Therapeutics Soars 5.11% as Evercore ISI Maintains Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dianthus Therapeutics Soars 5.11% as Evercore ISI Maintains Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-12 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught investors' attention as it demonstrates significant upward momentum.</p>\n\n<p>The surge comes after Evercore ISI analyst Gavin Clark-Gartner reiterated a Buy rating on Dianthus Therapeutics stock. In a report released on Monday, Clark-Gartner maintained an optimistic outlook for the company, setting a price target of $50 for DNTH shares. This target suggests substantial upside potential from the stock's current trading levels.</p>\n\n<p>Analyst ratings often play a crucial role in shaping investor sentiment, particularly for biotech companies like Dianthus Therapeutics. The maintained Buy rating and the ambitious price target indicate Evercore ISI's confidence in the company's pipeline and future prospects. As investors digest this positive assessment, it appears to be driving increased interest and buying activity in DNTH stock during the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNTH","symbol_name":"Dianthus Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1197688629","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197688629","pubTimestamp":1755007736,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNTH":"Dianthus Therapeutics Inc."},"translate_title":"股票追踪|Evercore ISI维持买入评级，Dianthus Therapeutics飙升5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNTH":1},"content_text":"Shares of Dianthus Therapeutics Inc. (DNTH) are soaring 5.11% in Tuesday's pre-market trading session, following a positive analyst report from Evercore ISI. The biotech company's stock has caught investors' attention as it demonstrates significant upward momentum.\nThe surge comes after Evercore ISI analyst Gavin Clark-Gartner reiterated a Buy rating on Dianthus Therapeutics stock. In a report released on Monday, Clark-Gartner maintained an optimistic outlook for the company, setting a price target of $50 for DNTH shares. This target suggests substantial upside potential from the stock's current trading levels.\nAnalyst ratings often play a crucial role in shaping investor sentiment, particularly for biotech companies like Dianthus Therapeutics. The maintained Buy rating and the ambitious price target indicate Evercore ISI's confidence in the company's pipeline and future prospects. As investors digest this positive assessment, it appears to be driving increased interest and buying activity in DNTH stock during the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}